Featured News
(OBR) Dec 11, 2020 - An all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) and other endpoints, compared with capecitabine alone, in patients with HER2-negative, hormone...
(OBR) Dec 11, 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple...
(OBR) Dec 11, 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near...
(OBR) Dec 10, 2020 - The addition of 1 year of the CDK4/6 inhibitor palbociclib to endocrine therapy did not improve invasive disease-free survival (IDFS) in hormone receptor (HR)-positive, HER2-negative primary breast cancer in patients...
(OBR) Dec 10, 2020 - Women who undergo mastectomy and reconstruction surgery may face the risk of long-term dependence on opioids and sedative-hypnotic drugs, according to research presented at the 2020 San Antonio Breast Cancer...
(Fred Hutch) Dec 18, 2020 - Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more.
(Morningstar) Dec 17, 2020 - Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight...
(MedPage Today) Dec 13, 2020 - Adding the investigational agent ipatasertib to paclitaxel failed to improve progression-free survival (PFS) in patients with PIK3CA/AKT1/PTEN-altered advanced triple-negative breast cancer, a researcher...
(Puma) Dec 11, 2020 - Puma Biotechnology, Inc., a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS) metastases at baseline, with a...
(Odonate) Dec 11, 2020 - CONTESSA achieved primary endpoint – tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) versus the approved dose of capecitabine alone (hazard ratio=0.716;...
(SABCS 2020) Dec 11, 2020 - One of the enduring problems in treating ER+ breast cancer is its persistent tendency to recur. HER+ and triple negative breast cancers usually recur within the first few years after treatment, but ER+ cancers...
(Gilead) Dec 10, 2020 - Gilead Sciences, Inc. is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer...
(SABCS 2020) Dec 11, 2020 - Recovering from breast cancer means more than good clinical outcomes. The overarching goal is good quality of life, which means balancing clinical outcomes with treatment toxicities while preserving a positive...
(OBR) Dec 11, 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple...
(OBR) Dec 11, 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near...